Mercado de dispositivos de administración de insulina en Asia y el Pacífico: tendencias de la industria y pronóstico hasta 2030

 Análisis y tamaño del mercado de dispositivos de administración de insulina en Asia-Pacífico

Según la décima edición del Atlas de la Diabetes publicado por la Federación Internacional de Diabetes (FID), 537 millones de personas en todo el mundo tendrán diabetes en 2045, frente a los 643 millones estimados para 2030. Además, el estudio señala que el 79% de los adultos con diabetes residen en países de ingresos bajos y medios. Además, un informe de la OMS de 2021 estima que la diabetes contribuyó directamente a 1,5 millones de muertes en 2019. Para controlar adecuadamente la diabetes, es probable que haya una mayor demanda de dispositivos de administración de insulina a medida que aumente la prevalencia de la diabetes entre la población.

Data Bridge Market Research analiza que el mercado de dispositivos de administración de insulina, que es de USD 3.81 mil millones en 2022, se espera que alcance los USD 6.50 mil millones para 2030, a una CAGR del 6,9% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de dispositivos de administración de insulina en Asia y el Pacífico  

Definición de mercado

Insulin is a hormone that controls glucose levels in the body. It is crucial to many people's recovery from advanced type II diabetes mellitus, also known as T2DM, and type I diabetes mellitus, also known as T1DM. Glucose can be produced and utilized as energy in adipose and muscular tissues by being transferred from the circulation by insulin. It cannot be administered orally or as a tablet because digestive acids and enzymes break down insulin before it enters the bloodstream. As a result, the fat tissue absorbs the insulin injection.

Asia-Pacific Insulin Delivery Devices Market Dynamics

Drivers

• Rise of insulin delivery devices

The rising incidence of diabetes significantly influences the rise of insulin delivery devices. The industry is anticipated to develop significantly due to the desire for insulin delivery devices since this is a dependable alternative and delivers patient satisfaction as the population of people with diabetes continues to increase daily. In the upcoming years, it's anticipated that there will be 700 million diabetic patients, which will cause the industry to expand. The market for insulin delivery devices is anticipated to gain from the rise in type 1 diabetes cases. Type 1 diabetes necessitates extremely intense insulin therapy in order to survive. Type 1 diabetes is distinguished by the body's inability to produce insulin. The favorable reimbursement policies supported by the governments of various nations are those that are celebrating the market's growth. As diabetes-related healthcare expenditures rise in many emerging economies, the market for insulin delivery devices is expected to expand during the forecast period.

• Rise in the cases of diabetes

The creation and endorsement of cutting-edge insulin delivery systems for the management of type I diabetes, which has a prevalence of 9.5% and an incidence of 15 cases per 100,000 people, according to an NCBI 2020 article. Type 1 diabetes prevalence and incidence worldwide, a systematic review and meta-analysis by Mobasseri M. also expected to drive the market for insulin delivery devices. For instance, the MiniMed 770G System, a hybrid closed-loop diabetes management device, was approved by the U.S. Food and Drug Administration (FDA) in 2020. It is intended to monitor glucose (sugar) automatically and provide the proper basal insulin doses with little to no input from the users or their carers for use by children and young adults with type diabetes. These are the certain factors which propel the market growth.

Opportunities

• Technological advancements in insulin delivery devices

The market is anticipated to experience growth due to manufacturers' increasing focus on creating smart insulin pens coupled with real-time continuous glucose monitoring data to enable effective diabetes treatment for patients. For instance, Medtronic just introduced InPenTM, the first and only FDA-cleared smart insulin pen for people who require numerous daily injections, in the year 2020. InPenTM is coupled with real-time Guardian ConnectTM CGM data (MDI).

Restraints/Challenges

• Risks associated with the insulin delivery devices

The horrifying routines of food consumption and smoking are unhealthy ways of life. These behaviors increase the risk of type 2 diabetes. One of the major causes of diabetes type 2 risk factors is work culture. Cigarette smoking should also be avoided because it increases the risk of developing type 2 diabetes compared to nonsmokers.

This insulin delivery devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the insulin delivery devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Insulin Delivery Devices Market

The COVID-19 epidemic had a severe effect on every industry in the world. However, this pandemic had a favourable effect on the market for insulin delivery devices. The rising prevalence of diabetes and obesity were two of the main causes of this favorable effect. Due to the pandemic's breakout condition, the demand for protective equipment including insulin delivery devices, such as insulin pumps, pens and syringes, among others, unexpectedly increased. This pandemic posed a serious threat to the population, which is also the reason for the rise in demand for protective gear and the upward trajectory of this market's revenue growth. In the year 2020, COVID-19 pandemic plays a very significant role in the expansion of insulin delivery devices. Furthermore, well-known market companies who compete in this industry have benefited from this favorable effect by streamlining their revenue streams and expanding their reach around the globe.

Recent Developments

• In 2022, Novo Nordisk launched smart insulin in the United Kingdom. The introduction of this novel product will contribute to the company's industrial position in the new K region.
• In 2020, A next-generation closed-loop insulin pump system for treating type 1 diabetes in patients aged 7 to 80, the MiniMedTM 780G system from Medtronic got CE (Conformité Européenne) Marking.
• In 2020, Abbott and Insulet Corporation signed a partnership agreement to combine Abbott's glucose-sensing technology with Insulet's cutting-edge tubeless system, the Omnipod HorizonTM Automated Insulin Delivery (AID) System (Omnipod Horizon System), to provide individuals with diabetes with personalized automated insulin delivery and care.

Asia-Pacific Insulin Delivery Devices Market Scope

The insulin delivery devices market is segmented on the basis of type, application, distribution channels and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Insulin Pumps
• Tubed/Tethered
• Tubeless
• Insulin Pens
• Reusable
• Disposable
• Insulin Pen needles
• Standard
• Safety​​​​​​​
• Insulin Jet Injectors
• Insulin Syringes
• Others

Application

• Type I Diabetes
• Type II Diabetes 

End User

• Home Care
• Hospitals & clinics
• Others

Distribution Channels

• Online Sales
• Hospital Pharmacies
• Retail Pharmacies
• Other Clinics

Insulin Delivery Devices Market Regional Analysis/Insights

The insulin delivery devices market is analyzed and market size insights and trends are provided by country, type, application, distribution channels and end-user as referenced above.

The countries covered in the insulin delivery devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

China is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to emerging countries in terms of GDP, the existence of a sizable population affected by diabetes, and the growing awareness of the disease among people.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.

Crecimiento de la infraestructura de atención de salud Base instalada y penetración de nuevas tecnologías

El mercado de dispositivos de administración de insulina también le proporciona un análisis detallado del mercado para cada país: crecimiento del gasto sanitario en equipos de capital, base instalada de diferentes tipos de productos para el mercado de dispositivos de administración de insulina, impacto de la tecnología mediante curvas de línea de vida y cambios en los escenarios regulatorios de la atención médica y su impacto en el mercado de dispositivos de administración de insulina. Los datos están disponibles para el período histórico 2011-2021.

Análisis del panorama competitivo y de la cuota de mercado de los dispositivos de administración de insulina

El panorama competitivo del mercado de dispositivos de administración de insulina proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de dispositivos de administración de insulina.

Algunos de los principales actores que operan en el mercado de dispositivos de administración de insulina son:

• BD (Estados Unidos)
• Medtronic (Irlanda)
• Ypsomed (Suiza)
• Novo Nordisk India Pvt Ltd (India)
• Beta Bionics Inc. (Estados Unidos)
• Owen Mumford Ltd. (Reino Unido)
• Sanofi (Francia)
• Tandem Diabetes Care, Inc. (Estados Unidos)
• Copérnico (Polonia)
• Corporación Insulet (Estados Unidos)
• Biocon (India)
• Eli Lilly and Company (Estados Unidos)
• Servicios farmacéuticos de West, Inc. (Estados Unidos)
• F. Hoffmann-La Roche Ltd (Suiza)
• Debiotech SA (Suiza)
• InsuJet (Países Bajos)
• SHL (Reino Unido)
• SOOIL Developments Co., Ltd (Corea del Sur)

SKU-1550